At Jounce, our overarching vision is to create long-lasting treatments to transform the way cancer is treated. This vision is brought to life by our Cancer Hero Wall – a daily reminder of why we come to work each day and the potential impact we can have on patient lives.

Our focus on patients goes beyond developing cancer therapies. At Jounce, we factor the patient into every step of the process. We conduct biomarker analyses of patient populations in clinical trials with an aim to match the right immunotherapy to the right patients. The potential benefit of this approach to cancer patients is two-fold: shorter development times to deliver novel therapies to patients with unmet needs and improved treatment outcomes. If successful, we will make a meaningful and long-lasting impact on the lives of cancer patients.

Hero Wall

Jounce Cancer Hero Wall

Why we do what we do:

Jouncers describe what motivates them each day.

Cancer Immunotherapy

Cancer immunotherapy aims to treat patients by mobilizing the immune system to recognize and attack tumors. Based on the groundbreaking initial research and discoveries by our founders, we aim to revolutionize the immunotherapy field through our translational science platform.

Mobilizing the Immune System to Attack Cancer

Our research and development strategy is to target specific mechanisms that match the composition of the immune system within the human tumor microenvironment (TME), with the goal of transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and bring long-lasting benefits to patients.

What makes us different

Advancing a pipeline of innovative cancer therapies

Immunotherapies are increasingly recognized as a critical component of cancer therapy and are beginning to fundamentally change the paradigm for treating patients. However, due to a general lack of predictive biomarkers to identify responsive patient populations, fewer than half of all cancer patients respond to these immunotherapies as single agents. Combination therapies are beginning to yield greater responses than single agent therapies, although there is still significant unmet medical need across large patient populations.

Developing unparalleled immunologic insights into tumors in order to match the right therapies to the right patients

Our Translational Science Platform utilizes a suite of integrated technologies to profile the immune cellular and molecular characteristics within thousands of human solid tumors, providing critical information on the tumor micro-environment (TME) that allows us to identify and guide new immunotherapies more efficiently through development. We utilize a systematic approach to match targets to defined patient populations that we believe are more likely to benefit from these therapies – allowing us to distinguish and prioritize targets versus making a more random choice. If our biomarker-driven strategies are successful, we anticipate developing a companion diagnostic for each product. We believe that we can facilitate a systematic means of novel immunotherapy discovery, enroll biomarker-defined patient populations in clinical trials, and develop therapies, alone or in combination, that will have a meaningful and long-lasting impact on the lives of cancer patients.


Thomas Gajewski

Congratulations to Thomas Gajewski, recipient of the 2019 ESMO Award for Immuno-Oncology


Updated strategic collaboration with Celgene

  • Licensed worldwide rights to JTX-8064
  • Retained full worldwide rights to vopratelimab, JTX-4014 and all discovery programs


Vopratelimab EMERGE clinical trial initiation


Nobel Prize in Physiology or Medicine

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation


Padmanee Sharma

Jounce Therapeutics co-founder Padmanee Sharma, M.D., Ph.D. awarded the William B. Coley Award for Distinguished Research in Tumor Immunology for her innovative work understanding factors that enhance and hinder cancer immunotherapy.


Jim Allison

Jounce founder, Jim Allison receives the Lasker-DeBakey Clinical Medical Research Award



Vopratelimab ICONIC trial initiation

August 2015

Keytruda and Opdivo

Keytruda® and Opdivo® (Anti-PD-1), (immune checkpoint therapies) approved; additional clinical trials indicate activity in several cancers


Jounce expands application

Jounce expands application of translational science platform to Beyond T cells and initiates series of programs targeting myeloid and other cell types


Jounce Launches

Jounce launched by Third Rock Ventures and founders, James P. Allison, Ph.D., Thomas F. Gajewski, M.D., Ph.D., Drew Pardoll, M.D., Ph.D, Robert Schreiber, Ph.D, Padmanee Sharma, M.D., Ph.D., Louis M. Weiner, M.D.

February 2013


Yervoy® anti-CTLA-4 approved for advanced melanoma


jounce founders publish

Brad Carthon and Jounce founders Pam Sharma and Jim Allison’s publication on enhanced survival related to up-regulation of ICOS on T cells in Clinical Cancer Research


preclinical evidence ctla-4

Preclinical evidence from Jim Allison of enhanced anti-tumor immunity by CTLA-4 published in Science


pd-1 receptor

PD-1 receptor (immune checkpoint) identified by Tasuku Honjo


Scroll to Learn More